NPPA Fixes Retail Rates for 36 Key Drugs Like Atorvastatin, Dapagliflozin, Gemcitabine
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed retail prices of 36 formulations under the Drugs (Prices Control) Order (DPCO), 2013.
The authority has fixed the retail prices based on the decision of the 142nd Authority meeting dated 30.01.2026.
The list of formulations that have come under retail price fixation includes Atorvastatin plus Ezetimibe Tablets in multiple strengths manufactured and marketed by Pure & Cure Healthcare/Mankind Pharma and Macleods Pharmaceuticals; Cefuroxime Axetil + Potassium Clavulanate Tablets manufactured and marketed by Theon Pharmaceuticals/Emcure Lifesciences; Clindamycin and Tretinoin Gel manufactured and marketed by Om Sai Pharma Pack/Cipla; Dapagliflozin and Telmisartan Tablets manufactured and marketed by Exemed Pharmaceuticals/Eris Lifesciences and others.
The notification was issued in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Mankind Pharma Ltd. | 20.00 |
2 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Mankind Pharma Ltd. | 25.00 |
3 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Mankind Pharma Ltd. | 31.90 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
4 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 20.98 |
5 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 30.10 |
6 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 31.90 |
7 | Calcium Citrate, Vitamin D3, Methylcobalamin, Pyridoxine HCL and Folic Acid Tablets | Each Film Coated Tablet Contains: Calcium Citrate USP 1000 mg Vitamin D3 IP 200 IU Methylcobalamin IP 500 mcg Pyridoxine Hydrochloride IP 10 mg Folic Acid IP 5 mg | 1 Tablet | M/s Troikaa Pharmaceuticals Ltd. | 14.37 |
8 | Cefuroxime Axetil and Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Anhydrous Cefuroxime 250 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg | 1 Tablet | M/s Theon Pharmaceuticals Ltd./ M/s Emcure Lifesciences Pvt. Ltd. | 38.14 |
9 | Cefuroxime Axetil and Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Anhydrous Cefuroxime 500 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg | 1 Tablet | M/s Theon Pharmaceuticals Ltd./ M/s Emcure Lifesciences Pvt. Ltd. | 63.94 |
10 | Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Dextromethorphan Hydrobromide Syrup | Each 5 ml contains: Chlorpheniramine Maleate IP 2 mg Phenylephrine Hydrochloride IP 5 mg Dextromethorphan Hydrobromide IP 10 mg | 1 ml | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 0.98 |
11 | Ciprofloxacin and Tinidazole Tablets | Each film coated tablet contains: Ciprofloxacin Hydrochloride IP Eq. to Ciprofloxacin 500mg Tinidazole IP 600mg | 1 Tablet | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 8.00 |
12 | Clindamycin and Tretinoin Gel | Composition: Clindamycin Phosphate IP Equivalent to Clindamycin 1.0% w/w Tretinoin USP 0.025% w/w (As microspheres) | 1 gm | M/s Om Sai Pharma Pack/ M/s Cipla Ltd. | 7.78 |
13 | Combikit of Clarithromycin Tablets, Esomeprazole Tablets and Amoxicillin Tablets | Composition: Each Strip Contains:
Each Film Coated Tablet Contains: Clarithromycin IP 500 mg
| 1 kit | M/s Malik Lifesciences Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 167.21 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Tablets Each Enteric Coated Tablet Contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40 mg C. Amoxicillin Tablets USP 2 Tablets Each Film Coated Tablet Contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 1000 mg | |||||
14 | Dapagliflozin and Telmisartan Tablets | Each film coated tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg Telmisartan IP 40 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Eris Lifesciences Ltd. | 18.56 |
15 | Diclofenac Injection 1ml Glass Ampoule | Each ml contains: Diclofenac Sodium IP 75 mg | 1 ml | M/s Nitin Lifesciences Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 32.99 |
16 | Diclofenac Potassium and Serrattiopeptidase Tablets | Each enteric coated tablet contains: Diclofenac Potassium IP 50 mg Serrattiopeptidase IP 10 mg (Eq.to 20,000 units of enzyme activity) | 1 Tablet | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 3.05 |
17 | Enteric Coated Pantoprazole and Sustained Release Levosulpiride Capsules | Each hard gelatin capsule contains: Pantoprazole Sodium Sesquihydrate IP Equivalent to Pantoprazole 40 mg (As enteric coated pellets) Levosulpiride 75 mg (As sustained release tablet) | 1 Capsule | M/s Innova Captab Ltd./ M/s Emcure Pharmaceuticals Ltd. | 20.13 |
18 | Gliclazide modified-release and Metformin HCL extended release Tablets | Each uncoated bi-layered tablet contains: Gliclazide IP 30mg (in modified- release form) Metformin Hydrochloride IP 500mg (in extended release form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 7.92 |
19 | Gliclazide modified-release and Metformin HCL extended release Tablets | Each uncoated bi-layered tablet contains: Gliclazide IP 60mg (in modified- release form) Metformin Hydrochloride IP 500mg (in extended release form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 10.00 |
20 | Mefenamic Acid and Dicyclomine Tablets | Each film coated tablet contains: Mefenamic Acid IP 250 mg Dicyclomine Hydrochloride IP 10 mg | 1 Tablet | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 3.05 |
21 | Meropenem and Sulbactam for Injection | Each Combi Pack contains: A) Each Vial contains: Meropenem I.P Equivalent to Meropenem (Anhydrous) 1g Sodium (as Sodium Carbonate I.P) 90.2mg Sulbactam Sodium I.P | 1 vial | M/s Venus Remedies Ltd. | 1835.79 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Equivalent to Sulbactam 500 mg B) One ampoule of solvent contains: Sterile Water for Injections I.P 20 ml | |||||
22 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharma Laboratories Limited | 23.59 |
23 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Macleods Pharmaceuticals Ltd. | 23.59 |
24 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zydus Healthcare Ltd. | 23.59 |
25 | Paracetamol, Phenylephrine Hydrochloride, Caffeine and Diphenhydramine Hydrochloride Tablets | Each Film Coated Tablet Contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 5mg Caffeine (Anhydrous) IP 30mg Diphenhydramine Hydrochloride IP 25 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. | 4.64 |
26 | Paracetamol, Phenylephrine Hydrochloride, Caffeine and Diphenhydramine Hydrochloride Tablets | Each uncoated tablet contains: Paracetamol IP 500 mg Phenylephrine HCl IP 5 mg Caffeine (Anhydrous) IP 30 mg Diphenhydramine HCI IP 25 mg | 1 Tablet | M/s Innova Captab Ltd./ M/s Softdeal Pharmaceutical Pvt. Ltd. | 4.64 |
27 | Telmisartan, Cilnidipine and Chlorthalidone Tablets | Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Glenmark Pharmaceuticals Ltd. | 16.40 |
28 | Empagliflozin, Linagliptin, Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Linagliptin 5 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s. Abbott Healthcare Pvt. Ltd. | 20.27 |
29 | Empagliflozin, Sitagliptin, Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s. Abbott Healthcare Pvt. Ltd. | 19.80 |
30 | Empagliflozin, Sitagliptin, Metformin Hydrochloride | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP Equivalent to | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s. Abbott Healthcare Pvt. Ltd. | 21.43 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Extended Release Tablets | Sitagliptin 100 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | ||||
31 | Empagliflozin, Linagliptin, Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg Linagliptin 5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s MSN Laboratories Pvt. Ltd. | 20.27 |
32 | Cetirizine Ophthalmic Solution 0.24% w/v | Each ml Contains: Cetirizine Hydrochloride IP Eq. to Cetirizine 0.24 % w/v Benzalkonium Chloride Solution IP 0.02 % v/v (As preservative) | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Dr. Reddys Laboratories Ltd. | 14.42 |
33 | Cetirizine Ophthalmic Solution 0.24% w/v | Each ml Contains: Cetirizine Hydrochloride IP Eq. to Cetirizine 0.24 % w/v Benzalkonium Chloride Solution IP 0.02 % v/v (As preservative) | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd. | 14.42 |
34 | Ready to use Infusion bags Gemcitabine Hydrochloride Injection 10mg/ml (1200mg/ 120ml) | Each ml contains: Gemcitabine Hydrochloride IP equivalent to Gemcitabine 10 mg Sodium Chloride IP 9 mg | 1 Bag | M/s Sun Pharmaceutical Industries Ltd./ M/s Sun Pharma Laboratories Ltd. | 5977.68 |
35 | Ready to use Infusion bags Gemcitabine Hydrochloride Injection 10mg/ml (1400mg/ 140ml) | Each ml contains: Gemcitabine Hydrochloride IP equivalent to Gemcitabine 10 mg Sodium Chloride IP 9 mg | 1 Bag | M/s Sun Pharmaceutical Industries Ltd./ M/s Sun Pharma Laboratories Ltd. | 7183.04 |
36 | Ready to use Infusion bags Gemcitabine Hydrochloride Injection 10mg/ml (1600mg/ 160ml) | Each ml contains: Gemcitabine Hydrochloride IP equivalent to Gemcitabine 10 mg Sodium Chloride IP 9 mg | 1 Bag | M/s Sun Pharmaceutical Industries Ltd./ M/s Sun Pharma Laboratories Ltd. | 8079.63 |
The notification further added
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official order, click the link below:
